VIENNA, Austria and KING OF PRUSSIA, Pa., March 24, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today provided a business and clinical development update and reported its financial results for the year ended December 31, 2016.
“For the last 12 months, we have been executing our clinical development program and are continuing to make progress enrolling our ongoing pivotal Phase 3 clinical trials—known as LEAP 1 and LEAP 2—evaluating lefamulin for the treatment of patients with moderate to severe community-acquired bacterial pneumonia (CABP),” said Dr. Colin Broom, Chief Executive Officer of Nabriva. “This is poised to be a potentially transformational year for Nabriva, as we expect top-line clinical data from LEAP 1 in the third quarter of 2017. In addition, based on current projections, we expect to complete patient enrollment for LEAP 2 in the fourth quarter of 2017 and we anticipate receiving top-line data for LEAP 2 in the first quarter of 2018.”
